The company had posted a profit of Rs 11.57 crore in the same period of the previous year, Lincoln Pharmaceuticals said in a statement.
Revenue from operations rose by 13.5 per cent to Rs 183.08 crore in the quarter under review compared to Rs 161.30 crore reported in the last quarter of FY25, it added.
For the full 2025-26 fiscal, Lincoln Pharma reported over 6 per cent growth in consolidated net profit to Rs 87.89 crore compared to the net profit of Rs 82.35 crore in FY25.
Revenue from operations for FY26 was reported at Rs 704.48 crore as compared to revenue of Rs 645.71 crore reported in FY25, registering a growth of 9.10 per cent Y-o-Y, the statement said.
The company said its board has recommended a dividend of 18 per cent, Rs 1.80 per share on the face value of Rs 10 per share for the FY 2025-26.
The company said it is targeting a revenue of Rs 1,000 crore within the next three years, driven by business expansion into high-value product lines and entry into new markets. PTI